{
    "nctId": "NCT00191438",
    "briefTitle": "Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents",
    "officialTitle": "Phase III Study of Docetaxel in Combination With Gemcitabine Versus Docetaxel in Combination With Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Progression free survival. The final analysis will occur when 250 patients have progressed or died.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced and/or metastatic breast cancer.\n* Measurable disease\n* Previously treated with anthracycline\n\nExclusion Criteria:\n\n* Patients with inflammatory breast disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}